Higher Doses of Pfizer Alzheimer’s Drug Trigger Ban Request

Higher doses of an Alzheimer’s drug sold by Eisai Co. and Pfizer Inc. endanger patients and don’t enhance the treatment’s effectiveness, according to a consumer group that wants the regimen banned.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.